EOPC mortality declined significantly over 2 decades, likely reflecting broader uptake of multimodal therapy among younger patients, but improvements were not evenly distributed, with persistent disparities among non-Hispanic Black individuals, males, and rural populations. These findings highlight ongoing inequities in pancreatic cancer outcomes and the need for targeted public health and research efforts to address disparities in early-onset disease.
Orhin et al. (Mon,) studied this question.